- Short Report
- Open Access
Allele frequencies of the human platelet antigen-1 in the Egyptian population
BMC Research Notesvolume 2, Article number: 90 (2009)
The human platelet alloantigen system HPA-1 in the Egyptian population was examined by polymerase chain reaction using sequence-specific primers (PCR-SSP). The objectives of this study were to evaluate the allele frequency of HPA-1a and -1b in healthy Egyptian individuals and compare these with the international literature. Human platelet antigen (HPA) systems are associated with alloimmunization and organ transplantation rejection as well as the development of cardiovascular disease. Of the various HPA systems, HPA-1 specifically has been considered to be the most important antigenic system implicated in the Caucasian population. No study has yet examined this system in the Egyptian populations, however. We therefore investigated the allele frequency of the HPA-1 system in the Egyptian population.
To determine the allele frequency of the HPA-1a and -1b, we tested genomic DNAs from 206 healthy, unrelated Egyptian individuals using PCR-SSP. Our results showed that the 1a/1a genotype was the most predominant (59.22%) followed by 1a/1b (34.95%) and 1b/1b (5.83%) with allele frequencies for 1a and 1b of 0.77 and 0.23, respectively, in the population.
As compared with other geographic groups, a relatively high allele frequency of the HPA-1b in the Egyptian population may indicate a higher risk of alloimmunization. This study is the first to investigate the allele frequency of the HPA-1 system in the Egyptian population and serves as an outline for future clinical research associated with platelet disorders in this group.
The human platelet antigens (HPA) systems derive from the single base pair substitution in the encoding genes of platelet membrane glycoproteins (GP). The GP variants resulting from amino acid substitutions are involved in the rate of alloimmunization to platelet-specific antigens. Subsequently, the alloimmunization can induce neonatal alloimmune thrombocytopenia (NAIT) , post-transfusion purpura (PTP), or platelet transfusion refractoriness (PTR) . Therefore, accurate donor compatibility for platelet transfusions is extremely important. HPA systems are not only associated with organ transplantation rejection  and cardiovascular disease , but are also frequently assessed in general population studies. The molecular basis of the biallelic polymorphisms of all HPA systems (i.e. HPA-1, 2, -3, -4, -5, -15) is linked to platelet GP variants. The major GPs (GPIIb, GPIIIa, GPIb, and GPIa) generated by single amino acid substitutions are associated with various HPAs . The presence of leucine or proline at position 33 of the GPIIIa results in two HPA-1a or HPA-1b antigens, respectively . Therefore, molecular DNA-based analysis has been preferred for the HPA genotyping.
Recent studies of population genetics have reported that there is a heterogeneous diversity of HPA genotypes in different geographic groups. However, these studies have largely been performed in Asian, European, and North American populations [7–9]. Among Arabian populations, Egyptians are among the most centrally located to Africa, Europe, and Asia. This fact resulted in Egypt's varied cultural history and its population is a diverse genetic amalgam. To date, the HPA-1 polymorphisms have not been assessed in the Egyptian population. The aim of this study was to investigate the allele frequencies of HPA-1 and estimate the frequency of the 1a and 1b alleles among the healthy Egyptian population.
Samples and DNA extraction
Blood samples were collected from 206 unrelated, healthy Egyptians from Ismailia under institutionally approved internal review board protocols with informed consent. DNA was prepared from blood leukocytes by standard methods . The genotypes of HPA-1 system were determined using the polymerase chain reaction sequence-specific primers (PCR-SSP) method designed by Skogen et al. and the SSPs were used to discriminate between the alleles encoding the six major HPAs in a series of patients and normal blood donors . The thermocycler program consists of an initial step of 94°C for 5 min, followed by 32 cycles of 94°C for 30 s, 65°C for 60 s, 72°C for 60 s, and a final extension step of 72°C for 10 min. The PCR products (15 ul) were subjected to gel electrophoresis on standard 1.5% agarose gel containing 0.5 ug per ml of ethidium bromide. The typing results were examined under UV light transillumination. For each sample, it was possible to determine the absence or presence of the two alleles, 1a and 1b. Individuals are, therefore, genotypically classified as 1a/1a, 1a/1b or 1b/1b.
Statistical analysis was performed using SPSS version 15 statistical package for windows. Allele and genotype frequencies were calculated by direct counting; Hardy-Weinberg equilibrium was assessed by an exact test provided by the Arlequin program .
Results and discussion
The genotype and allele frequencies of HPA-1 system in the Egyptian population are shown in Table 1. The study population was found to be in Hardy-Weinberg equilibrium. The 1a/1a genotype is the most predominant (59.22%) followed by 1a/1b (34.95%) and 1b/1b (5.83%) (Table 1). In these 206 unrelated Egyptian individuals, the allele frequencies of 1a and 1b were calculated to be 0.77 and 0.23, respectively. Table 2 describes the allele frequencies at the HPA-1 with those previously reported in other ethnic populations.
The allele frequencies of several of HPAs vary among different ethnic groups and their prevalence in a given population is a major determinant for the prevalence of HPA alloimmunization and its clinical associated entities: NAIT, PTP, PTR, post-transfusion passive alloimmune thrombocytopenia, and transplantation-associated alloimmune thrombocytopenia . In one study, HPA-1 antibodies were found to be present in 80% of patients with NAIT, and the HPA-1a allele was concluded to be a factor contributing to the disease . Although alloantibodies against the HPA-1 are frequently implicated in alloimmunization, the detection of HPA-1 is not recommended in African-American and Asian geographic groups because of the low allele frequency of the HPA-1b allele in these populations . As shown in Table 2, the allele frequency of HPA-1b for the African-American population is in fact lower than that for the Caucasian-American population (0.080 vs. 0.110). Furthermore, antibodies against HPA-1 antigens were extremely rare in Japanese patients with NAIT or refractoriness to platelet transfusion, with an allele frequency of 0.002 for anti-HPA-1b . Halle et al. recently studied four different sub-Saharan African populations (Beninese, Cameroonians, Congolese, and Pygmies) and the allele HPA-1b was reported to be somewhat low by contrast to other HPA systems (HPA-2, -3, -4, -5, -15) . By contrast, the allele frequency of HPA-1b in Aka Pygmy populations was 0.000, a result that might explain the low risk of alloimmunization anti-HPA-1a compared with Caucasian populations .
An increasing number of population genetic studies have been conducted to assess the effect of the HPA-1 system on the risk of developing cardiovascular disease or myocardial infarction (MI). However, the data obtained to date contained contradictions, and the correlation is still under debate. Weiss et al. reported that HPA-1b increases the risk of MI or unstable angina in Caucasian populations . The ratio of developing MI or unstable angina between patients with the HPA-1a/1a genotype and those with either the HPA-1a/1b or the 1b/1b genotype was found to be 6:2 . Other studies highlighted the effect of HPA-1 in coronary artery disease and showed a positive correlation in the same age group , as well as in the Caucasian population . By contrast, studies of the Japanese  and Korean  populations failed to demonstrate a significant correlation between HPA-1 and the risk of coronary artery disease or MI. Even in Caucasian populations, many studies did not detect any relationship .
As shown in Table 2, the Egyptians show an HPA-1 allele frequency that is similar to previously studied Arab populations (Tunisian, Moroccan, and Bahraini) except for the Lebanese [21–24]. The Egyptians have a slightly higher frequency of HPA-1b when compared to the Caucasian population (European and White American) [8, 25–28]. The Berbers (Morocco) have been shown to have the highest frequency for the HPA-1b allele . This is in contrast to the Asian populations and, in particular, the Amazon Indian population, which was shown to have total absence of the HPA-1b allele . The relatively high allele frequency of the HPA-1b in the Egyptian population suggests that this ethnic group has a higher risk of alloimmunization. This is the first to study the allele frequency of the HPA-1 system in this population and, to date, there are no data available on the effect of HPA-1 on the risk of developing alloimmunization, cardiovascular disease, or MI among Egyptian patients. Although the prevalence of NAIT, PTP, and PTR has not been established in the Egyptian population yet, the detection of HPA alloantibodies before any transfusion or pregnancy should be recommended to prevent any clinical condition, especially when there is a positive family history of cardiovascular disease. This is because platelet hyperactivity caused by a conformational change in the GP receptors on the platelet surface may confer an increased risk for cardiovascular disease. The authors believe that this study will serve as a baseline for future clinical research associated with platelet disorders or cardiovascular diseases associated with the Egyptian population.
Mueller-Eckhardt C: Post-transfusion purpura. Br J Haematol. 1986, 64: 419-424. 10.1111/j.1365-2141.1986.tb02198.x.
Borne von dem AE, Decary F: ICSH/ISBT Working Party on platelet serology. Nomenclature of platelet-specific antigens. Vox Sang. 1990, 58: 176-10.1111/j.1423-0410.1990.tb02085.x.
Kekomaki S, Kyllonen L, Salmela K, Koskimies S, Kekomaki R: Platelet-specific alloantigens in cadaveric renal transplantation. A prospective study. Effect of HPA-5b mismatch in acute vascular rejection of renal allografts. Tissue Antigens. 2001, 57: 154-157. 10.1034/j.1399-0039.2001.057002154.x.
Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, et al: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999, 94: 46-51.
Valentin N, Newman PJ: Human platelet alloantigens. Curr Opin Hematol. 1994, 1: 381-387.
Newman PJ, Derbes RS, Aster RH: The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989, 83: 1778-1781. 10.1172/JCI114082.
Holensteiner A, Walchshofer S, Adler A, Kittl EM, Mayr WR, Panzer S: Human platelet antigen gene frequencies in the Austrian population. Haemostasis. 1995, 25: 133-136.
Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF: Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion. 1995, 35: 863-867. 10.1046/j.1537-2995.1995.351096026369.x.
Seo DH, Park SS, Kim DW, Furihata K, Ueno I, Han KS: Gene frequencies of eight human platelet-specific antigens in Koreans. Transfus Med. 1998, 8: 129-132. 10.1046/j.1365-3148.1998.00138.x.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A laboratory Manual. 1989, Cold Spring Harbor Laboratory Press Cold Spring Harbor (NY)
Skogen B, Bellissimo DB, Hessner MJ, Santoso S, Aster RH, Newman PJ, McFarland JG: Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers. Transfusion. 1994, 34: 955-960. 10.1046/j.1537-2995.1994.341195065032.x.
Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evolutionary Bioinformatics Online. 2005, 1: 47-50.
De La Vega Elena CD, Nogues N, Fernandez Montoya A, Chialina S, Blanzaco PD, Theiller E, Raillon MA, Arancegui N, Solis E, Oyonarte S, et al: Human platelet-specific antigens frequencies in the Argentinean population. Transfus Med. 2008, 18: 83-90. 10.1111/j.1365-3148.2007.00819.x.
Tanaka S, Ohnoki S, Shibata H, Okubo Y, Yamaguchi H, Shibata Y: Gene frequencies of human platelet antigens on glycoprotein IIIa in Japanese. Transfusion. 1996, 36: 813-817. 10.1046/j.1537-2995.1996.36996420760.x.
Halle L, Bigot A, Mulen-Imandy G, M'Bayo K, Jaeger G, Anani L, Martageix C, Bianchi F, Julien E, Kaplan C: HPA polymorphism in sub-Saharan African populations: Beninese, Cameroonians, Congolese, and Pygmies. Tissue Antigens. 2005, 65: 295-298. 10.1111/j.1399-0039.2005.00360.x.
Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996, 334: 1090-1094. 10.1056/NEJM199604253341703.
Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L: Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost. 2001, 85: 626-633.
Carter AM, Ossei-Gerning N, Grant PJ: Platelet glycoprotein IIIa PlA polymorphism in young men with myocardial infarction. Lancet. 1996, 348: 485-486. 10.1016/S0140-6736(05)64592-8.
Hato T, Minamoto Y, Fukuyama T, Fujita S: Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol. 1997, 80: 1222-1224. 10.1016/S0002-9149(97)00645-0.
Park S, Park HY, Park C, Ko YG, Im EK, Jo I, Shin C, Lee JB, Shim WH, Cho SY, Jang Y: Association of the gene polymorphisms of platelet glycoprotein Ia and IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population. Yonsei Med J. 2004, 45: 428-434.
Al-Subaie AM, Al-Absi IK, Al-Ola K, Saidi S, Fawaz NA, Almawi WY: Gene frequencies of human platelet alloantigens in Bahraini Arabs. Am J Hematol. 2007, 82: 242-244. 10.1002/ajh.20769.
Ferrer G, Muniz-Diaz E, Aluja MP, Arilla M, Martinez C, Nogues R, Servin A, Baali A: Analysis of human platelet antigen systems in a Moroccan Berber population. Transfus Med. 2002, 12: 49-54. 10.1046/j.1365-3148.2002.00349.x.
Mojaat N, Halle L, Proulle V, Hmida S, Ben Hamed L, Boukef K, Kaplan C: Gene frequencies of human platelet antigens in the Tunisian population. Tissue Antigens. 1999, 54: 201-204. 10.1034/j.1399-0039.1999.540214.x.
Sabbagh AS, Taher AT, Zaatari GS, Mahfouz RA: Gene frequencies of the HPA-1 platelet antigen alleles in the Lebanese population. Transfus Med. 2007, 17: 473-478.
Drzewek K, Brojer E, Zupanska B: The frequency of human platelet antigen (HPA) genotypes in the Polish population. Transfus Med. 1998, 8: 339-342. 10.1046/j.1365-3148.1998.00164.x.
Merieux Y, Debost M, Bernaud J, Raffin A, Meyer F, Rigal D: Human platelet antigen frequencies of platelet donors in the French population determined by polymerase chain reaction with sequence-specific primers. Pathol Biol (Paris). 1997, 45: 697-700.
Muniz-Diaz E, Arilla M, Ibanez M, Bosch MA, Pastoret C, Madoz P: [Frequency of platelet alloantigens in the Spanish population]. Sangre (Barc). 1993, 38: 289-293.
Steffensen R, Kaczan E, Varming K, Jersild C: Frequency of platelet-specific alloantigens in a Danish population. Tissue Antigens. 1996, 48: 93-96. 10.1111/j.1399-0039.1996.tb02613.x.
Chiba AK, Bordin JO, Kuwano ST, Figueiredo MS, Carvalho KI, Vieira-Filho JP, Kerbauy J: Platelet alloantigen frequencies in Amazon Indians and Brazilian blood donors. Transfus Med. 2000, 10: 207-212. 10.1046/j.1365-3148.2000.00254.x.
We are grateful to J. A. Walker for her help throughout this project. This work was supported by National Science Foundation grant BCS-0218338 (MAB), and National Institutes of Health RO1 GM59290 (MAB).
The authors declare that they have no competing interests.
AHS designed the research project. AHS performed the experiments and analyzed data. MAB contributed reagents/materials/analytic tools. KH performed part of the experimental procedures and helped to draft the manuscript. AHS and MAB wrote the manuscript. All authors read and approved the final manuscript.